On May 27, 2026, Cardiosense announced that the U.S. Food and Drug Administration granted De Novo classification for its PCWP Analysis Software™, a first-in-class technology to estimate pulmonary capillary wedge pressure (PCWP) noninvasively in adults with heart failure. The software is intended for use with the company’s CardioTag™ wearable chest sensor, which received FDA 510(k) clearance in July 2025. Together, the sensor and software are authorized to market as Class II medical devices in the United States.
For patients with heart failure, fluid buildup is a leading driver of symptomatic decompensation and hospitalization. PCWP can rise before symptoms appear, but historically it was measured invasively with a catheter or implant inside the heart. Cardiosense positions its AI-powered software as a way to estimate that value using only the wearable sensor—supporting earlier detection and more proactive management in indicated patients. The company has cited prior publication in the Journal of the American College of Cardiology: Heart Failure and a presentation at the American Heart Association’s 2024 Scientific Sessions; any comparison to implanted pressure sensors should stay within published study context, not sales overclaim.
The De Novo indication is for adult patients with heart failure with reduced ejection fraction (HFrEF), left ventricular ejection fraction (LVEF) ≤ 40%, and New York Heart Association (NYHA) Functional Class II, III, or IV symptoms. Cardiosense has said it plans future algorithms for heart failure detection and heart failure with preserved ejection fraction (HFpEF)—those are pipeline goals, not part of the current label.
This is a software-plus-sensor medical device story—not cath lab capital equipment or implant case coverage. For medical sales professionals, the commercial motion spans heart failure clinics, cardiology practices, hospital quality and readmission programs, and disciplined digital deployment—not OR scheduling alone.
Why This Matters for Medical Sales Careers
- De Novo pathways create a new regulatory category—adoption cycles are often longer and more evidence-heavy than a straight 510(k) predicate swap
- Heart failure readmissions keep economic buyers in the room alongside cardiologists and advanced practice providers
- Reps need clinical literacy on PCWP, HFrEF, and decompensation risk without positioning the tool as a replacement for invasive measurement when clinicians still need it
- Strong candidates blend digital health skills—workflow integration, compliance stakeholders, realistic reimbursement talk—with relationship selling in cardio
- Do not confuse this launch with pharma hypertension brands or cath lab contrast systems; the stakeholder map and ramp metrics differ
Hiring and Interview Takeaways
Candidates should prepare examples of how they sold workflow change: clinician champions, pilot design, training plans, and expansion from one site to a broader program. Interviewers will care whether you can explain label scope, who signs off on new monitoring workflows, and how you handled stalled pilots—not just feature lists.
Employers hiring for “cardio digital” or “HF monitoring” territories should be explicit whether the role is disposable pull-through, software-enabled service, or a hybrid—and what year-one utilization targets look like during launch. Specialty mismatch between implant OR reps and outpatient HF programs is a common reason new hires underperform in the first year.